Onco'Zine - The International Cancer Network

11/19/2025

https://conta.cc/4qSUtMh

Antibody-drug conjugates (ADCs) are transforming therapeutic strategies—but their analytical development is anything but straightforward. Unlike small molecules or biologics, ADCs combine two modalities, creating unique challenges for scientists and developers.

07/30/2025

07/14/2025

New Staging Method for HPV-Positive Throat Cancer Gives Patients Better Information and a More Consistent Treatment

06/11/2025

Join us at the London Biotechnology Show 2025, where innovation meets opportunity! https://conta.cc/3HB1cZ0

Dear Reader, Join us at the London Biotechnology Show 2025, where innovation meets opportunity! Whether you are looking to explore the latest biotech breakthroughs with a complimentary Visitor Pass or gain premium access to industry leaders and exclusive content with a Delegate Pass, we have got the...

05/15/2025

The US Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis®, AbbVie; Previously known as ABBV-399)

The US Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis®, AbbVie; Previously known as ABBV-399; See Drug description and ADC Drugmap)*

05/14/2025

Email from Sunvalley Communication, LLC You don't want to miss this.   Conference Coverage   May 13, 2025 | 05   Highlights from the Annual Meeting of the American Association for Cancer Research (AAC

05/14/2025

A study by a team of researchers at the Karl Landsteiner University of Health Sciences in Austria (KL Krems) shows that higher radiation doses in lung cancer treatment carry no added risk of inflammation – and may improve survival.

The researchers found that that a higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy without increasing the risk of pneumonitis or severe lung inflammation. According to the researchers involved in the study, this is key finding of a recent study.

Click on the Link to read the Article

A study by a team of researchers at the Karl Landsteiner University of Health Sciences in Austria ((KL Krems) shows that higher radiation doses in lung cancer treatment carry no added risk of inflammation – and may improve survival.

05/14/2025

Although up to 50% of all cancers can be prevented by following lifestyle recommendations and health professional advice, Cancer remains a public health concerns worldwide. [1][2]

According to estimates by Globocan, the Global Cancer Observatory (GCO), there will be more than 18 million people alive with a history of invasive cancer in the United States. This includes individuals diagnosed many years prior. Additionally, over 2 million new cancer cases are expected to be diagnosed, and more than 618,000 deaths are projected to occur [1][2] Estimates suggest that by 2040 the global cancer burden will reach the level of 28 million new cases (a nearly 50% increase in comparison to 2020).

Click on the Link to Read the Article.

NCCN Oncology Policy Summit on building bridges between primary care and oncology for better treatment outcomes.

05/14/2025

Acalabrutinib (Calquence®; AstraZeneca) in combination with bendamustine (Treanda®; Cephalon, a subsidiary company of Teva Pharmaceutical) and rituximab (Rituxan® / MabThera®; Genentech/Roche) has been approved in the European Union (EU) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant.

MCL is a rare and typically aggressive form of non-Hodgkin lymphoma, often diagnosed at an advanced stage.

Click on the Link to Read the Article.

Acalabrutinib (Calquence®; AstraZeneca) in combination with bendamustine (Treanda®; Cephalon, a subsidiary company of Teva Pharmaceutical) and rituximab (Rituxan® / MabThera®; Genentech/Roche) has been approved in the European Union (EU) for the treatment of adult patients with previously untrea...

05/14/2025

A new global report published by the World Health Organization (WHO) highlights that the underlying causes of ill health often stem from factors beyond the healthcare, and may include lack of quality housing, education and job opportunities.

The report on social determinants of health equity shows that such determinants can be responsible for a dramatic reduction of healthy life expectancy – sometimes by decades – in high- and low-income countries alike.

Click on the Link to Read the Article.

A new global report published by the World Health Organization (WHO) highlights that the underlying causes of ill health often stem from factors beyond the healthcare, and may include lack of quality housing, education and job opportunities.

05/14/2025

Results from a retrospective study presented at the annual meeting of the American Association for Cancer Research (AACR) , held April 25-30, 2025 demonstrates that female cancer survivors were 69% more likely to experience cancer-related fatigue (CRF; odds ratio [OR] = 1.69; 95% CI = 1.24–2.31; P < .001) and 58% more likely to experience depression than male survivors (OR = 1.58; 95% CI = 1.10–2.26; P = .014). [1]

Cancer-related fatigue (CRF) and depression are prevalent and debilitating conditions among cancer survivors, leading to a decrease in recreational physical activities and health related Quality of Life (hrQoL).

The study-results indicate that overall, cancer survivors who reported feeling cancer-related fatigue or depression reduced their recreational activities nearly twofold, with females more likely than males to report feeling either cancer-related fatigue or depression.

Click on the Link to Read the Article.

Results from a retrospective study presented at the annual meeting of the American Association for Cancer Research (AACR) , held April 25-30, 2025 demonstrates that female cancer survivors were 69% more likely to experience cancer-related fatigue (CRF; odds ratio [OR] = 1.69; 95% CI = 1.24–2.31; P...

05/14/2025

While decision-making for genomics-driven therapy in patients with advanced, recurrent and/or metastatic, solid tumors is generally guided by results from a tissue biopsy, a question remained if a liquid biopsy, testing for circulating tumor DNA (ctDNA) for the genomic profiling of solid cancers could be beneficial. Which method would yield more accurate results and benefit treatment decision-making?

To answer the question, scientists in Italy developed a study to evaluate the efficacy (i.e overall response rate Objective Response Rate/ORR) of targeted therapy vs Standard of Care in patients with progressive disease of breast cancer, metastatic gastro-intestinal tumors, non small cell lung cancer (NSCLC) or others.

Click on the Link to read the article

While decision-making for genomics-driven therapy in patients with advanced, recurrent and/or metastatic, solid tumors is generally guided by results from a tissue biopsy, a question remained if a liquid biopsy, testing for circulating tumor DNA (ctDNA) for the genomic profiling of solid cancers cou...